secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001193125-23-193428
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BMF-219 induces 2 complete responses in 5 AML patients with menin mutations in Phase I trial
--------------------------------------------------------------------------------

- 2 of 5 relapsed/refractory AML patients with menin-dependent mutations achieved CRs at Dose Level 4 (500mg or 125mg QD).
- CRs observed within first two 28-day cycles; both patients continue on BMF-219 treatment.
- No dose-limiting toxicities or QTc prolongation reported; generally well tolerated.
- Dose Level 5 enrollment commenced to explore optimal biological dose.
- Biomea plans to present additional data at an upcoming medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/0001193125-23-193428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/d434383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-193428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer